Summit Therapeutics PLC
$ 14.29
1.28%
09 Jun - close price
- Market Cap 10,951,654,000 USD
- Current Price $ 14.29
- High / Low $ 14.68 / 14.02
- Stock P/E N/A
- Book Value 0.70
- EPS -1.59
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.48 %
- ROE -2.71 %
- 52 Week High 30.98
- 52 Week Low 13.81
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$28.51
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-23 | 2025-10-20 | 2025-08-11 | 2025-05-01 | 2025-02-24 | 2024-10-30 | 2024-08-06 | 2024-05-01 | 2024-02-20 | 2023-11-07 | 2023-08-09 |
| Reported EPS | -0.1767 | -0.3908 | -0.2315 | -0.12 | -0.0677 | -0.07 | -0.08 | -0.09 | -0.06 | -0.04 | -0.03 | -0.02 |
| Estimated EPS | -0.1217 | -0.08 | -0.1032 | -0.09 | -0.0682 | -0.08 | -0.07 | -0.06 | -0.06 | -0.05 | None | None |
| Surprise | -0.055 | -0.3108 | -0.1283 | -0.03 | 0.0005 | 0.01 | -0.01 | -0.03 | 0 | 0.01 | 0 | 0 |
| Surprise Percentage | -45.1931% | -388.5% | -124.3217% | -33.3333% | 0.7331% | 12.5% | -14.2857% | -50% | 0% | 20% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SMMT
2026-06-08 13:10:26
Summit Therapeutics experienced a 6.0% drop after presenting new Phase II and Phase III ivonescimab data at ASCO, particularly focusing on colorectal and lung cancer. Despite the strong objective responses shown, especially in first-line metastatic colorectal cancer, the company's investment narrative still hinges on regulatory approval and commercial uptake. The article highlights ivonescimab's potential across solid tumors and suggests that positive outcomes in ongoing Phase III trials could add a second major therapeutic pillar to Summit's portfolio.
2026-06-05 20:39:47
Summit Therapeutics Co-CEO Robert W. Duggan reported an indirect open-market purchase of 100,000 shares of common stock at $14.60 per share through the Mahkam Zanganeh Revocable Trust. This transaction increased the trust's holdings to 25,824,474 shares. The filing also detailed Duggan's direct holdings of over 570 million shares and other indirect holdings associated with various trusts and family members, with a disclaimer of beneficial ownership except for pecuniary interest.
2026-06-05 12:36:00
Summit Therapeutics (SMMT) presented new clinical data from its Phase II AK112-206 trial for ivonescimab in metastatic colorectal cancer, showing a 70.8% objective response rate in combination with chemotherapy. This data compares favorably to standard treatments. Despite promising results, Piper Sandler recently cut SMMT's price target to $16, maintaining a Neutral rating, as investors weigh the replicability of positive trial outcomes in ongoing larger studies.
2026-06-04 21:41:11
Summit Therapeutics (SMMT) co-CEO Mahkam Zanganeh, through her revocable trust, purchased 100,000 shares of common stock at $14.60 per share in an open-market transaction. This transaction increased the trust's holdings to over 25.8 million shares. The filing also detailed other significant holdings associated with Zanganeh, including those of her spouse and other trusts, while she disclaimed beneficial ownership beyond her pecuniary interest.
2026-06-04 20:41:11
Manmeet Singh Soni, COO and CFO of Summit Therapeutics (SMMT), purchased 50,000 shares of the company's common stock on June 4, 2026. The open-market transactions involved two buys of 25,000 shares each, at prices of $14.43 and $14.46, totaling $722,250. This increases his direct ownership to over three million shares, signaling positive insider sentiment.
2026-06-04 20:30:00
Summit Therapeutics Inc. announced its participation in the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the management team will present a corporate overview, including an update on their investigational bispecific antibody, ivonescimab, in a fireside chat at 10:00 AM ET. The presentation will be available live and archived on the company's website.
